Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease

International Journal of COPD

Volumn 10, Issue , 2015, Pages 909-915

  Fu, Alex Z ^a   Sun, Shawn X ^b   Huang, Xingyue ^b   Amin, Alpesh N ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Health Economics and Outcomes Research Forest Laboratories LLC an affiliate of Actavis Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; Health care utilization; Hospital readmission; Roflumilast

Indexed keywords

ROFLUMILAST; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PROPENSITY SCORE; RETROSPECTIVE STUDY; CHI SQUARE DISTRIBUTION; FACTUAL DATABASE; MIDDLE AGED; ODDS RATIO; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOPYRIDINES; BENZAMIDES; CHI-SQUARE DISTRIBUTION; CYCLOPROPANES; DATABASES, FACTUAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT READMISSION; PHOSPHODIESTERASE 4 INHIBITORS; PROPENSITY SCORE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84929406741     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S83082     Document Type: Article

References (24)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed January 15, 2014.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Available at: https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Accessed April 23, 2015.
3. Miniño AM, Xu J, Kochanek KD. Deaths: Preliminary data for 2008. Natl Vital Stat Rep. 2010;59(2):1–52.
4. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96(9):700–708.
5. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943.
6. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
7. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695–703.
8. US Food and Drug Administration. FDA approves new drug to treat chronic obstructive pulmonary disease. Available from: http://www.fda.gov/NewsEvents/newsroom/PressAnnouncements/ucm244989.htm. Accessed April 16, 2015.
9. Baye J. Roflumilast (Daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. P T. 2012;37(3):149–161.
10. Zhao Y, Ash AS, Ellis RP, et al. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Med Care. 2005;43(1):34–43.
11. Fu AZ, Chen L, Sullivan SD, Christiansen NP. Absenteeism and short-term disability associated with breast cancer. Breast Cancer Res Treat. 2011;130(1):235–242.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
13. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359–2367.
14. Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11:43.
15. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Paper 214-26 presented at the SAS Users Group 26th International Conference, Long Beach, CA, USA, April 22–25, 2001.
16. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294(23):1262–1267.
17. Field SK. Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations. Clin Med Insights Circ Respir Pulm Med. 2011;5:57–70.
18. Van de Griend JP, Marcum ZA, Linnebur SA. A year in review: new drugs for older adults in 2011. Am J Geriatr Pharmacother. 2012;10(4):258–263.
19. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143(5):1302–1311.
20. [No authors listed]. Roflumilast: doubtful efficacy but clear harms in COPD. Prescrire Int. 2013;22(134):5–9.
21. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45.
22. Vilkman S, Keistinen T, Tuuponen T, Kivela SL. Seasonal variation in hospital admissions for chronic obstructive pulmonary disease in Finland. Arctic Med Res. 1996;55(4):182–186.
23. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499.
24. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda: National Heart, Lung and Blood Institute, 2008. Available from: http://www.goldcopd.org/uploads/users/files/GOLDWkshp05Clean.pdf. Accessed April 16, 2015.